Poniard cuts more jobs on picoplatin suspension
This article was originally published in Scrip
Executive Summary
Poniard Pharmaceuticals has eliminated all staff working towards an NDA filing of its treatment for small-cell lung cancer (SCLC), picoplatin. The US company has hired an advisor to review its strategy, which could include a possible sale or merger of the business.